Tekmira merges with OnCore to find hep B cure
This article was originally published in Scrip
Executive Summary
Canada's Tekmira Pharmaceuticals has agreed to merge with US company OnCore Biopharma, bringing together the two companies' hepatitis B virus (HBV) candidates with hopes to find a curative combination therapy.